Trial Profile
Assessment of the procedural success of Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with chronic total occlusion lesions.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- 10 Sep 2015 New trial record